Treatment Approach for Bronchitis with Positive Bronchodilator Response

Significance of Bronchodilator Response

A 13% improvement in lung function test after bronchodilator use indicates airway reversibility, suggesting the patient would benefit from bronchodilator therapy, according to the American Thoracic Society 2
This response indicates that the chronic cough may be responsive to bronchodilator treatment, even if the patient is hesitant to use an inhaler, as recommended by the American College of Chest Physicians 1

The American College of Chest Physicians recommends ipratropium bromide with a grade A recommendation for improving cough in stable patients with chronic bronchitis 1
Ipratropium bromide has demonstrated more reliable effects on cough reduction compared to short-acting β-agonists, which show inconsistent results for cough improvement, as reported by the American College of Chest Physicians 1
The standard dosing is ipratropium bromide 36 μg (2 inhalations) four times daily, as recommended by the American College of Chest Physicians 1

Short-acting β-agonists can be considered as an alternative or add-on therapy to control bronchospasm and relieve dyspnea; in some patients, they may also reduce chronic cough, according to the American Thoracic Society 2
For patients with severe airflow obstruction or frequent exacerbations, consider adding an inhaled corticosteroid with a long-acting β-agonist, as recommended by the Global Initiative for Chronic Obstructive Lung Disease 3
Theophylline may be considered to control chronic cough in stable patients with chronic bronchitis, but careful monitoring for complications is necessary, as reported by the American Thoracic Society 2

Educate the patient about the demonstrated improvement in their lung function test, which indicates they would likely benefit from bronchodilator therapy, as recommended by the American College of Chest Physicians 1
Explain that ipratropium bromide has been shown to decrease cough frequency, cough severity, and volume of sputum expectorated in patients with chronic bronchitis, according to the American College of Chest Physicians 1

Start with ipratropium bromide 36 μg (2 inhalations) four times daily, as recommended by the American College of Chest Physicians 1
Monitor for improvement in cough frequency and severity after starting treatment, as recommended by the American College of Chest Physicians 1
If response to ipratropium bromide is inadequate after 2 weeks, consider adding a short-acting β-agonist for additional bronchodilation and potential cough relief, as recommended by the American College of Chest Physicians 1

Mistaking chronic bronchitis for acute bronchitis can lead to inappropriate treatment choices; the chronic nature of the tickle cough suggests chronic bronchitis rather than an acute condition, as reported by the American College of Chest Physicians 4
Using oral corticosteroids for long-term management of stable chronic bronchitis is not recommended due to lack of benefit and significant side effects, as recommended by the Global Initiative for Chronic Obstructive Lung Disease 3
Theophylline should not be used during acute exacerbations of chronic bronchitis, according to the American Thoracic Society 2

If the patient experiences an acute exacerbation, both short-acting β-agonists and anticholinergic bronchodilators should be administered, with the addition of the other agent at maximal dose if prompt response is not observed, as recommended by the American Thoracic Society 2
For acute exacerbations, a short course (10-15 days) of systemic corticosteroids may be beneficial, as recommended by the Global Initiative for Chronic Obstructive Lung Disease 3
Mucokinetic agents have limited evidence to justify their use for controlling cough in patients with chronic bronchitis, according to the American Thoracic Society 2